Printer Friendly

JONES MEDICAL TO PURCHASE 16.7 PERCENT EQUITY IN ABANA PHARMACEUTICALS

 JONES MEDICAL TO PURCHASE 16.7 PERCENT EQUITY IN ABANA
 PHARMACEUTICALS
 ST. LOUIS, Mo., May 6 /PRNewswire/ -- Jones Medical Industries, Inc. (NASDAQ: JMED) today signed a Letter Alabama, is a pharmaceutical marketer of specialty products to physicians and hospitals throughout Alabama, Georgia, Mississippi and Tennessee. JMED's capital infusion will assist Abana in aggressively expanding their sales organization from its present 10, to 65 sales representatives by the end of 1993.
 As Abana expands its sales organization, JMED will explore the viability of joint marketing certain products including JMED's "second generation" Thrombin products, which are expected to receive FDA approval in mid 1993.
 The Letter of Intent also provides JMED an option to increase its equity position via a $500,000 Convertible Debenture and for JMED to designate one of three directors to Abana's board of directors.
 The purchase of Abana shares is expected to be concluded by the end of May, 1992 subject to execution of the definitive agreement and the approval of both boards of directors.
 JMED recently announced record first quarter 1992 results with a 33 percent increase in earnings on a 35 percent increase in sales, over the same quarter of 1991.
 Jones Medical Industries, Inc. is a young, aggressive, growth oriented manufacturer and marketer of pharmaceutical and nutritional products. With the acquisition of Thrombinar in 1989 and GenTrac, Inc. in 1991 JMED has positioned itself to become a leader in the field of active topical hemostasis and wound care. JMED's goal is to continue its ten year history of record growth in both sales and earnings through strategic acquisition and focused internal development.
 -0- 5/6/92
 /CONTACT: Investor Relations 314-432-7557/
 (JMED) CO: Jones Medical Industries, Inc.; Abana Pharmaceuticals, Inc. ST: Missouri, Alabama IN: MTC SU:


LR -- NY072 -- 7190 05/06/92 14:54 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 6, 1992
Words:299
Previous Article:SMITHKLINE BEECHAM SHAREHOLDERS APPROVE CHANGE IN VOTING PROCEDURE
Next Article:SILICON GRAPHICS PROMOTES TECHNOLOGIST THOMAS JERMOLUK TO CHIEF OPERATING OFFICER


Related Articles
JONES MEDICAL INCREASES QUARTERLY DIVIDEND 33 PERCENT
JONES MEDICAL PURCHASES 16.7 PERCENT EQUITY IN ABANA PHARMACEUTICALS
JONES MEDICAL REPORTS UNUSUALLY LARGE APRIL 1993 THROMBINAR SALES
OWENS & MINOR, INC., ANNOUNCES IMPROVED 1993 SECOND QUARTER AND SIX-MONTH EARNINGS
QVC SECURES FINANCING TO COMPLETE TENDER OFFER FOR PARAMOUNT COMMUNICATIONS
COMMON STOCKS OF ICN PHARMACEUTICALS, THREE OPERATING UNITS, TOP MAJOR STOCK MARKET INDICES IN 1993
Class Action Commenced Against Manufacturers of Diet Pills Marketed as Fen/Phen and Redux
Cardinal Health Reports Record First-Quarter Earnings and Revenues Net Earnings Rise 24% on 16% Revenue Growth Before Special Items.
Firms showing increased profits.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters